Table 1.
Summary of the studies on non-COPD subjects vs COPD patients included in the meta-analysis.
| Non-COPD | COPD | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| First Author Year, Country |
Matrix Type |
n | Age Mean |
Gender (M/F) |
GPx Mean ± SD |
n | Age Mean |
Gender (M/F) |
GPX Mean ± SD |
| WHOLE BLOOD/ERYTHROCYTES | |||||||||
| Santos MC et al. 2004, Portugal |
Er | 24 | NR | NR | 0.092 ± 0.027 U/g Hb | 21 | NR | NR | 0.068 ± 0.027 U/g Hb |
| Nadeem A et al. 2005, India |
Er | 21 | NR | NR | 65.96 ± 13.56 mU/g Hb | 67 | NR | NR | 54.17 ± 16.12 mU/g Hb |
| Joppa P et al. 2007, Slovakia |
Er | 21 | 48 | 9/12 | 51.30 ± 14.66 U/g Hb | 75 | 65 | 58/17 | 41.80 ± 18.05 U/g Hb |
| Biljak VR et al. 2010, Croatia |
Er | 51 | 52 | 21/30 | 7904 ± 1096 U/L | 109 | 71 | 82/27 | 6418 ± 1657 U/L |
| Lakhdar R et al. 2011, Tunisia |
Er | 182 | 56 | 173/9 | 85.70 ± 13.61 U/g Hb | 234 | 62 | 222/12 | 63.66 ± 4.95 U/g Hb |
| Tavilani H et al. 2012, Iran |
Er | 60 | 67 | NR | 64.7 ± 31.70 U/g Hb | 30 | 66 | NR | 80.74 ± 46.50 U/g Hb |
| Ahmad H et al. 2013, India |
Er | 75 | 42 | 53/22 | 48.32 ± 14.20 U/g Hb | 140 | 45 | 111/29 | 43.04 ± 9.93 U/g Hb |
| Arja C et al. 2013, India |
Er | 150 | 61 | NR | 43.63 ± 1.61 U/g Hb | 236 | 63 | NR | 36.36 ± 4.57 U/g Hb |
| Wozniak A et al. 2013, Poland |
Er | 35 | 45 | 19/16 | 13.8 ± 46 U/g Hb | 108 | 49 | 61/47 | 8.4 ± 3.1 U/g Hb |
| Montoya-Estrada A et al. 2013, Mexico |
Er | 11 | 61 | 1/10 | 13.90 ± 1.98 mU/mg protein | 43 | 69 | 30/13 | 12.89 ± 2.51 mU/mg protein |
| Bukowska B et al. 2015, Poland |
Er | 18 | NR | NR | 53.66 ± 9.56 mU/g Hb | 30 | NR | NR | 43.70 ± 11.20 mU/g Hb |
| Elmasry SA et al. 2015, Egypt |
WB | 40 | 54 | 31/9 | 12.2 ± 0.7 U/mL | 34 | 55 | 27/7 | 12 ± 0.9 U/mL |
| Mohammed A et al. 2017, India |
Er | 59 | 51 | 38/21 | 63.77 ± 3.38 U/mg protein | 127 | 60 | 98/29 | 59.43 ± 5.63 U/mg protein |
| Di Stefano A et al. 2018, Italy |
WB | 27 | NR | 12/15 | 293 ± 332 U/mL | 45 | NR | 39/6 | 143 ± 159 U/mL |
| Al-Azzawi MA et al. 2019, Egypt |
Er | 40 | 45 | 28/12 | 47.5 ± 1.82 U/mL | 30 | 65 | 21/9 | 15.9 ± 1.2 U/mL |
| SERUM/PLASMA | |||||||||
| Premanand R et al. 1994, India |
S | 100 | NR | 60/40 | 0.231 ± 0.040 U/mL | 75 | NR | 43/32 | 0.204 ± 0.040 U/mL |
| Nadeem A et al. 2005, India |
P | 21 | NR | NR | 129.9 ± 24.1 mU/g Hb | 51 | NR | NR | 156.4 ± 30.8 mU/g Hb |
| Vibhuti A et al. 2007, India |
P | 136 | 50 | 110/26 | 19.1 ± 3.5 U/mL | 202 | 59 | 160/42 | 17.9 ± 7.1 U/mL |
| Montaño M et al. 2010, Mexico |
P | 30 | 65 | 0/30 | 0.11 ± 0.03 U/mL | 60 | 73 | 0/60 | 0.23 ± 0.22 U/mL |
| Wassem SM et al. 2012, India |
S | 60 | 38 | 46/14 | 57.21 ± 0.39 mU/mg protein | 121 | 48 | 80/41 | 51.46 ± 2.77 mU/mg protein |
| Zeng M et al. 2013, China |
P | 28 | 69 | 23/5 | 214.2 ± 6.9 U | 35 | 71 | 31/4 | 183.0 ± 4.6 U |
| Ben Anes A et al. 2014, Tunisia |
P | 229 | 58 | NR | 33.6 ± 24.1 U/ml | 153 | 61 | NR | 121.3 ± 33.0 U/ml |
| Ambade VN et al. 2015, India |
P | 96 | 60 | 73/23 | 50.95 ± 15.30 U/L | 96 | 68 | 73/23 | 89.73 ± 27.84 U/L |
| Hartmann SE et al. 2015, Canada |
P | 14 | 68 | 6/8 | 41.41 ± 8.75 U/ml | 12 | 69 | 4/8 | 36.41 ± 9.84 U/ml |
| Al-Azzawi MA et al. 2017, Egypt |
P | 80 | 53 | 62/18 | 11.98 ± 1.01 mU/ml | 80 | 55 | 58/22 | 12.13 ± 0.92 mU/ml |
Er = Erythrocytes; Hb: Haemoglobin; NR = Not reported; P = Plasma; S = Serum; WB = Whole Blood